Binding of growth hormone to liposomes
CA 2079443 C · Owner: Margalit, Rimona · Inventors: Margalit, Rimona
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Crosslinking reagents glutaraldehyde and ethylene glycol diglycidyl ether have been used to bind epidermal growth factor ("EGF") to liposomal surfaces without utilizing the disulfide bridge linkage of EGF and, therefore, not adversely affecting the functionality of EGF. The crosslinking occurs through the amine residues offered by EGF and liposomes having phosphatidylethanolamine. The resulting EGF-modified liposomes offer potential as a microscopic drug delivery system.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 30, 1991 and granted December 31, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 30, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 30, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.